Results 291 to 300 of about 10,851,050 (358)
Some of the next articles are maybe not open access.
Journal of Clinical Oncology, 2023
Purpose To evaluate the efficacy and safety of bevacizumab when added to first-line oxaliplatin-based chemotherapy (either capecitabine plus oxaliplatin [XELOX] or fluorouracil/folinic acid plus oxaliplatin [FOLFOX-4]) in patients with metastatic ...
L. Saltz +12 more
semanticscholar +1 more source
Purpose To evaluate the efficacy and safety of bevacizumab when added to first-line oxaliplatin-based chemotherapy (either capecitabine plus oxaliplatin [XELOX] or fluorouracil/folinic acid plus oxaliplatin [FOLFOX-4]) in patients with metastatic ...
L. Saltz +12 more
semanticscholar +1 more source
The Lancet, 2022
BACKGROUND Drug combinations rather than increasing doses of one drug can achieve greater efficacy and lower risks. Thus, as an alternative to high-intensity statin monotherapy, moderate-intensity statin with ezetimibe combination therapy can lower LDL ...
Byeong‐Keuk Kim +15 more
semanticscholar +1 more source
BACKGROUND Drug combinations rather than increasing doses of one drug can achieve greater efficacy and lower risks. Thus, as an alternative to high-intensity statin monotherapy, moderate-intensity statin with ezetimibe combination therapy can lower LDL ...
Byeong‐Keuk Kim +15 more
semanticscholar +1 more source
Monotherapy and Combination Therapy Using Anti‐Angiogenic Nanoagents to Fight Cancer
Advances in Materials, 2021Anti‐angiogenic therapy, targeting vascular endothelial cells (ECs) to prevent tumor growth, has been attracting increasing attention in recent years, beginning with bevacizumab (Avastin) through its Phase II/III clinical trials on solid tumors. However,
Pingping Liang +6 more
semanticscholar +1 more source
Neurological Sciences, 2006
So far, off-label recommendation of a combination therapy is mainly based on phase II study evidence and on largely accepted expert opinions. Combination therapy represents a new, more global strategy, to increase the possible benefits with the combined use of already available disease-modifying therapies or with other new agents, having an acceptable ...
openaire +3 more sources
So far, off-label recommendation of a combination therapy is mainly based on phase II study evidence and on largely accepted expert opinions. Combination therapy represents a new, more global strategy, to increase the possible benefits with the combined use of already available disease-modifying therapies or with other new agents, having an acceptable ...
openaire +3 more sources
Combination Intravesical Therapy
Urologic Clinics of North America, 2020After Bacillus Calmette-Guerin (BCG) failure, there is likely a 6- to 24-month window whereby salvage intravesical therapy might allow for preservation of the bladder without disease worsening. Combination intravesical, salvage therapy for nonmuscle invasive bladder cancer represents a promising avenue for treatment in patients unfit or unwilling to ...
Nathan A, Brooks, Michael A, O'Donnell
openaire +2 more sources
Respiratory Care Clinics of North America, 2001
Although not allowing one to state conclusively that a particular combination of approaches to CMV and adjuncts to CMV affect outcome, the results are encouraging. Independently, none of the modalities discussed-HFV, ECMO, NO, or PLV-have shown a statistically significant improvement in outcome except NO.
openaire +3 more sources
Although not allowing one to state conclusively that a particular combination of approaches to CMV and adjuncts to CMV affect outcome, the results are encouraging. Independently, none of the modalities discussed-HFV, ECMO, NO, or PLV-have shown a statistically significant improvement in outcome except NO.
openaire +3 more sources
Medical Journal of Australia, 1978
Fifty-two cases of advanced head and neck cancer were treated by 434-MHz radiowave hyperthermia which was combined with cobalt radiotherapy and/or radioactive gold grain implant. Complete resolution of primary and secondary lesions occurred in 94% of cases, and the survival rate after three years was 54%.
A J, Nelson, J A, Holt
openaire +3 more sources
Fifty-two cases of advanced head and neck cancer were treated by 434-MHz radiowave hyperthermia which was combined with cobalt radiotherapy and/or radioactive gold grain implant. Complete resolution of primary and secondary lesions occurred in 94% of cases, and the survival rate after three years was 54%.
A J, Nelson, J A, Holt
openaire +3 more sources
2015
Immunotherapy of cancer encompasses different strategies that elicit or enhance the immune response against tumors. The first results from clinical studies have provided promising data for the treatment of lung cancer patients with immunomodulating monotherapies.
Niels, Reinmuth, Martin, Reck
openaire +2 more sources
Immunotherapy of cancer encompasses different strategies that elicit or enhance the immune response against tumors. The first results from clinical studies have provided promising data for the treatment of lung cancer patients with immunomodulating monotherapies.
Niels, Reinmuth, Martin, Reck
openaire +2 more sources